Advertisement

Picture EBD Group Digital Medicine & Medtech Showcase 2021 at BTS2021 651x81
Organisation › Details

Boehringer Ingelheim Venture Fund (BIVF)

Created in 2010, the Boehringer Ingelheim Venture Fund GmbH (BIVF) invests in groundbreaking therapeutics-focused biotechnology companies to drive innovation in biomedical research. BIVF is searching for significant enhancements in patient care through pioneering science and its clinical translation by building long-term relationships with scientists and entrepreneurs. BIVF’s focus is to target unprecedented therapeutic concepts addressing high medical needs in immuno-oncology, in regenerative medicine or infectious diseases. These may include novel platform technologies to address so far undruggable targets, new generation vaccines and/or new biological entities, such as oncolytic virotherapy as well as Digital Health. BIVF takes an active role within its portfolio companies – delivering significant added value through its own extensive drug discovery, scientific and managerial expertise. BIVF has € 300 million under management and currently supervises a portfolio of 29 companies. *

 

Period Start 2010-03-01 established
Products Industry venture capital
  Industry 2 pharmaceutical
Person Person Kalkbrenner, Frank (Boehringer 201308 CVP + Head of BIVF + CEO Acousia Therapeutics GmbH)
     
Region Region Ingelheim
  Country Germany
  Street 173 Binger Str.
  City 55216 Ingelheim
  Tel +49-6132-77-8740
    Address record changed: 2010-09-18
     
Basic data Employees n. a.
  Currency EUR
  Annual sales 300,000,000 (capital under management (2020) 2020-07-21)
     
    * Document for �About Section�: Quantro Therapeutics GmbH. (7/21/20). "Press Release: Quantro Therapeutics Launched with Breakthrough Oncology Drug Discovery Platform". Vienna.
     
   
Record changed: 2020-10-20

Advertisement

Picture [iito] Plain Stupid Simple 650x80px

More documents for Boehringer Ingelheim Venture Fund (BIVF)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80




» top